Related Experiment Video
Updated: Aug 7, 2025

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
Rare Dysfunctional Complement Factor I Genetic Variants and Progression to Advanced Age-Related Macular Degeneration
Johanna M Seddon1, Bernard Rosner2, Dikha De1
1Department of Ophthalmology and Visual Sciences, University of Massachusetts Chan Medical School, Worcester, Massachusetts.
Insights
Rare dysfunctional complement factor I (CFI) variants significantly increase the risk of developing advanced age-related macular degeneration (AMD) with geographic atrophy (GA). This finding highlights CFI's role in AMD progression.
Area of Science:
- Ophthalmology
- Genetics
- Molecular Biology
Background:
- Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults.
- Genetic factors play a significant role in AMD pathogenesis.
- Complement factor I (CFI) is involved in regulating the complement system, a key component of the immune response.
Purpose of the Study:
- To investigate the association between rare dysfunctional complement factor I (CFI) genetic variants and the progression to advanced AMD, specifically geographic atrophy (GA) and neovascular disease (NV).
Main Methods:
- A prospective, longitudinal study involving 4953 participants aged 55-80 with non-advanced AMD at baseline.
- Genotyping and sequencing were used to identify rare CFI variants, categorized as type 1 (associated with low factor I protein levels and function).
- Generalized estimating equations were employed to assess the association between CFI variants and AMD progression, adjusting for genetic and environmental factors.
Main Results:
- 1% of participants were identified as type 1 rare CFI carriers.
- CFI carriers showed a significantly higher progression rate to advanced AMD (44% vs. 20%), GA (30% vs. 10%), and NV (18% vs. 11%) over 12 years compared to non-carriers.
- CFI carrier status was independently associated with GA progression (OR=1.91) and a higher baseline AMD grade.
- Higher body mass index (BMI ≥ 25) was associated with increased AMD progression specifically in CFI carriers (OR=5.8).
Conclusions:
- Carriers of rare dysfunctional type 1 CFI variants face a substantially elevated risk of progressing to advanced AMD with geographic atrophy.
- These findings underscore the critical role of the complement system, particularly CFI, in AMD development and progression.
- Elevated BMI may exacerbate AMD progression in individuals with specific CFI genetic profiles.
Purpose:
To evaluate associations between rare dysfunctional complement factor I (CFI) genetic variant status and progression to advanced age-related macular degeneration (AAMD), geographic atrophy (GA), and neovascular disease (NV).
Design:
Prospective, longitudinal study.
Participants:
Patients aged 55 to 80 years at baseline identifying as White with non-AAMD in 1 or both eyes at baseline were included. Follow-up grades were assigned as early, intermediate, or AAMD (GA or NV). CFI variants were categorized using genotyping and sequencing platforms.
Methods:
Analyses were performed using the Seddon Longitudinal Cohort Study (N = 2116 subjects, 3901 eyes, and mean follow-up of 8.3 years) and the Age-Related Eye Disease Study (N = 2837 subjects, 5200 eyes, and mean follow-up of 9.2 years). CFI rare variants associated with low serum factor I (FI) protein levels and decreased FI function (type 1), other AMD genetic variants, and demographic, behavioral, and ocular factors were evaluated. Generalized estimating equations methods were used to assess the association between CFI rare variants and progression, independent of other genetic variants and covariates.
Main Outcome Measures:
Progression to AAMD, GA, or NV.
Results:
In the prospective cohort of 4953 subjects (9101 eyes with non-AAMD at baseline), 1% were type 1 rare CFI carriers. Over 12 years, progression to AAMD was 44% for carriers and 20% for noncarriers (P < 0.001), 30% of carriers versus 10% of noncarriers progressed to GA (P < 0.001), and 18% of carriers compared with 11% of noncarriers progressed to NV (P = 0.049). CFI carriers were more likely to have a family history of AMD (P for trend = 0.035) and a higher baseline AMD grade (P < 0.001). After adjusting for all covariates, CFI carrier status was associated with progression to GA (odds ratio [OR] = 1.91; 95% confidence interval [CI] = 1.03, 3.52) but not NV (OR = 0.96). Higher body mass index was associated with progression among CFI carriers (body mass index ≥ 25 vs. < 25; OR = 5.8; 95% CI 1.5, 22.3) but not for noncarriers (OR = 1.1; 95% CI = 0.9, 1.3), with P_interaction = 0.011.
Conclusions:
Results suggest that carriers of rare dysfunctional type 1 CFI variants are at higher risk for progression to AAMD with GA.
Financial Disclosures:
Proprietary or commercial disclosure may be found after the references.
Related Concept Videos
iPS Cell Differentiation
Photoreceptors and Visual Pathways
Genetic Lingo
Translation
Translation Produces the Building Blocks of Life
Proteins are...

